
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics Inc. is advancing its clinical-stage product candidate ML-007C-MA, designed to provide a differentiated treatment option for schizophrenia and Alzheimer's disease psychosis, showing promising preclinical data with significant improvements in sociability and aggression in relevant mouse models. Phase 1 and preclinical data indicate that ML-007C-MA may achieve better tolerability and dosing convenience compared to currently available medications, which could facilitate its adoption in the market. The therapeutic's favorable pharmacokinetics and safety profile, coupled with compelling target differentiation in circuit-specific pharmacotherapies, position MapLight favorably within the biopharmaceutical landscape.
Bears say
The analysis indicates a negative outlook on MapLight Therapeutics's stock due to several factors, including its late entry into a highly competitive schizophrenia market, where expectations for success are tempered by previous marketing performances of similar drugs with minimal differentiation. Concerns regarding the clinical trial process, including potential conduct issues and delays, have contributed to skepticism around the company's first-phase three readout and elevated the perceived risk profile of its product candidate. Moreover, the current market capitalization of approximately $800 million appears undervalued based on projected peak sales; however, if approval probabilities are lowered to 15%, the discounted cash flow valuation per share could significantly decrease, further underscoring the financial uncertainties associated with the company's prospects.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares